Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-614-9 | CAS number: 108-77-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP and some deviations from OECD guidelines.
Data source
Reference
- Reference Type:
- publication
- Title:
- Cyanuric chloride (2,4,6-trichloro-1,3,5-triazine): 90-days repeated exposure inhalation toxicity study in rats
- Author:
- Jedrychowski R.
- Year:
- 1 994
- Bibliographic source:
- The Nofer intitute of occupational medicine, Lodz, Poland
- Report date:
- 1994
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- The list of examined organs is not fully in accordance with OECD 413; Air changes were below OECD recommendations (10-12/h rec.)
- Qualifier:
- according to guideline
- Guideline:
- other: EEC 84/449/EEC.
- GLP compliance:
- no
Test material
- Reference substance name:
- 2,4,6-trichloro-1,3,5-triazine
- EC Number:
- 203-614-9
- EC Name:
- 2,4,6-trichloro-1,3,5-triazine
- Cas Number:
- 108-77-0
- Molecular formula:
- C3Cl3N3
- IUPAC Name:
- 2,4,6-trichloro-1,3,5-triazine
- Details on test material:
- purity >95%.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: DAK Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 6-8 weeks old
weighing 145-190 g (males) and 120-160 g (females)
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- Air changes 7.2/hour.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyses of test substance: 0.012, 0.051 and 0.241 mg/m3 for nominal concentrations of 0.01, 0.05 and 0.25 mg/m3 resp.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 days per week, 6 hours per day
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.01, 0.05 and 0.25 mg/m3
Basis:
- No. of animals per sex per dose:
- 10/sex/treatment
- Control animals:
- other: air-exposed controls
Examinations
- Observations and examinations performed and frequency:
- General:
Mortality daily; Clinical signs daily before and after exposure; Body weight at study initiation and weekly thereafter; Food consumption.
Clinical pathology:
Blood chemistry at end of treatment period: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), sorbitol dehydrogenase (SDH), γ-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), ornithine carbamoyltransferase (OCT), total billirubin, total protein, albumin, blood urea nitrogen (BUN), glucose, natrium, potassium, chloride, inorganic phosphate and calcium; Hematology at end of treatment period: red blood cell count (RBC), white blood cell count (WBC), hemoglobin, hematocrit value, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), platelet count, percentage of reticulocytes and differential leukocyte count.
Necropsy:
Macroscopy: external appearance, body orifices, body cavities and their contents; Organ weights: brain, lungs, heart, liver, kidneys, adrenals, thymus, ovaries/testes and spleen; Histopathology: nose, trachea, lungs, heart, liver, kidneys, adrenal gland, spleen, stomach, duodenum, pancreas, small and large intestine, testes and epididymides/uterus and ovaries, brain, cerebellum, (para)thyroid, salivary gland, thymus, oesophagus, mediastinal lymph nodes, urinary bladder, prostate gland, seminal vesicles, mammary glands, lacrimal glands, eye with optic nerve, skin, femur muscles, spinal cord and spinal medulla.
Analysis of test substance:
Analysis of test substance concentrations at least every two hours by gas chromatography. - Statistics:
- Bartlett’s test for homogeneity of variance, ANOVA, Dunnett’s test, Kruskal-Wallis test, Dunn’s summed rank test, Jonkheere’s test for trend and ANCOVA.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Phosphate, Glucose
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Testes, Adrenals, Heart
- Details on results:
- Macroscopy: Consisting an of increased amount of yellowish exudate in the nose of males (6/10), and congested lungs. In control and other treatment groups incidence of exudate was 0-1/10 males and 2/10 females
Microscopy:
Nose : Presence of PMN in the lumen
Trachea (tracheitis): Incidence 5/10. Also findings in females. Increased incidence at all treatment groups and controls (1-3/10)
Bronchi: Higher incidence of increased cellularity of BALT in high dose males compared to control and other groups.
Lungs: Congestion and/or foamy macrophages in alveoli and/or interstitial lymphocytic infiltrations; effects in females appeared less frequently.
Small intestine: Proliferation of lymphatic tissue
Liver: Fast red (+) droplets in hepatocytes
Testes/epidymides/prostate/seminal vesicles: No treatment related effects
Uterus/ovaries: No treatment related effects
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Remarks:
- for systemic toxicity
- Effect level:
- 0.25 mg/m³ air
- Dose descriptor:
- NOAEC
- Remarks:
- for local effects
- Effect level:
- 0.05 mg/m³ air
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Analyses of test substance: 0.012, 0.051 and 0.241 mg/m3 for nominal concentrations of 0.01, 0.05 and 0.25 mg/m3 resp.
Applicant's summary and conclusion
- Conclusions:
- NOAEC = 0.25 mg/m3 for systemic toxicity.
NOAEC = 0.05 mg/m3 for local effects. - Executive summary:
A 90-days repeated exposure inhalation toxicity study for Cyanuric chloride was carried out in rats. The number of animals was 10/sex/treatment. Doses of 0.01, 0.05 and 0.25 mg/m3 were studied, as well as air-exposed controls, according to a whole-body inhalation exposure system. The exposure period was 13 weeks. Mortality, clinical signs, body weight, food compsumption, clinical pathology and necropsy were observed. The test substance concentrations was also analysed.
The results were as follows:
NOAEC = 0.25 mg/m3for systemic toxicity.NOAEC = 0.05 mg/m3for local effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.